Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update

Integrin Alpha 4 is a protein encoded by ITGA4. This integrin is a therapeutic target for the treatment of multiple sclerosis, Crohn’s disease, and inflammatory bowel disease. The Integrin Alpha 4 drugs in development market research report provides in-depth analysis of Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted pipeline therapeutics. The report provides comprehensive information on the Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.

What are the therapy areas of the Integrin Alpha 4 pipeline drugs market?

The therapy areas of the Integrin Alpha 4 pipeline drugs market are gastrointestinal, central nervous system, immunology, infectious disease, oncology, ophthalmology, genetic disorders, musculoskeletal disorders, and respiratory.

Integrin Alpha 4 pipeline drugs market, by therapy areas

For more therapy area insights, download a free report sample

What are the indications of the Integrin Alpha 4 pipeline drugs market?

Some of the indications of the Integrin Alpha 4 pipeline drugs market are inflammatory bowel disease, Crohn’s disease (regional enteritis), ulcerative colitis, relapsing remitting multiple sclerosis (RRMS), graft versus host disease (GVHD), multiple sclerosis, secondary progressive multiple sclerosis (spms), acute myelocytic leukemia (AML, Acute Myeloblastic Leukemia), age-related macular degeneration, and amyotrophic lateral sclerosis.

Integrin Alpha 4 pipeline drugs market, by indications

For more indications insights, download a free report sample

What are the mechanisms of action of the Integrin Alpha 4 pipeline drugs market?

The mechanisms of action of the Integrin Alpha 4 pipeline drugs market are Integrin Alpha 4 Antagonist, Integrin Alpha 4 Inhibitor, and Integrin Alpha 4 Agonist.

Integrin Alpha 4 pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Integrin Alpha 4 pipeline drugs market?

The routes of administration in the Integrin Alpha 4 pipeline drugs market are oral, intravenous, subcutaneous, inhalational, intramuscular, topical, intraperitoneal, and ophthalmic.

Integrin Alpha 4 pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Integrin Alpha 4 pipeline drugs market?

The molecule types in the Integrin Alpha 4 pipeline drugs market are monoclonal antibody, small molecule, synthetic peptide, antisense oligonucleotide, and monoclonal antibody conjugated.

Integrin Alpha 4 pipeline drugs market, by molecule types

For more molecule type insights, download a free report sample

Which are the key companies in the Integrin Alpha 4 pipeline drugs market?

Some of the key companies in the Integrin Alpha 4 pipeline drugs market are Takeda Pharmaceutical Co Ltd, Antisense Therapeutics Ltd, Aviara Pharmaceuticals Inc, AxeroVision Inc, Biogen Inc, C4X Discovery Holdings Plc, DiCE Molecules SV Inc, EA Pharma Co Ltd, Feramda Ltd, Genentech USA Inc, Gilead Sciences Inc, Immunwork Inc, and Morphic Therapeutic Inc.

Integrin Alpha 4 pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

This report provides:

• A snapshot of the global therapeutic landscape of Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4).
• Reviews of pipeline therapeutics for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• Key players involved in Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) therapeutics and enlists all their major and minor projects.
• Assessment of Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
• Summaries of all the dormant and discontinued pipeline projects.
• Reviews of the latest news related to pipeline therapeutics for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4).

Reasons to Buy

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies.
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Identify and understand the targeted therapy areas and indications for Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) Identify the use of drugs for target identification and drug repurposing.
• Identify potential new clients or partners in the target demographic.
• Develop strategic initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics.
• Devise corrective measures for pipeline projects by understanding Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) development landscape.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.